[go: up one dir, main page]

DE60208044D1 - Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung - Google Patents

Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung

Info

Publication number
DE60208044D1
DE60208044D1 DE60208044T DE60208044T DE60208044D1 DE 60208044 D1 DE60208044 D1 DE 60208044D1 DE 60208044 T DE60208044 T DE 60208044T DE 60208044 T DE60208044 T DE 60208044T DE 60208044 D1 DE60208044 D1 DE 60208044D1
Authority
DE
Germany
Prior art keywords
acylaminothiazol
derivatives
preparation
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60208044T
Other languages
English (en)
Other versions
DE60208044T2 (de
Inventor
Cointet Paul De
Pierre Despeyroux
Daniel Frehel
Chantal Guenet
Corinne Heckel
Jean-Pierre Maffrand
Rebecca Pruss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0207222A external-priority patent/FR2840899B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of DE60208044D1 publication Critical patent/DE60208044D1/de
Publication of DE60208044T2 publication Critical patent/DE60208044T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE60208044T 2001-08-06 2002-08-05 Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung Expired - Lifetime DE60208044T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0110504 2001-08-06
FR0110504 2001-08-06
FR0207222A FR2840899B1 (fr) 2002-06-12 2002-06-12 Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
FR0207222 2002-06-12
PCT/FR2002/002802 WO2003014095A1 (fr) 2001-08-06 2002-08-05 Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique

Publications (2)

Publication Number Publication Date
DE60208044D1 true DE60208044D1 (de) 2006-01-19
DE60208044T2 DE60208044T2 (de) 2006-08-17

Family

ID=26213132

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60208044T Expired - Lifetime DE60208044T2 (de) 2001-08-06 2002-08-05 Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung

Country Status (10)

Country Link
US (2) US7288659B2 (de)
EP (1) EP1417189B1 (de)
JP (1) JP2005500370A (de)
AR (1) AR039059A1 (de)
AT (1) ATE312828T1 (de)
DE (1) DE60208044T2 (de)
DK (1) DK1417189T3 (de)
ES (1) ES2254773T3 (de)
TW (1) TWI318974B (de)
WO (1) WO2003014095A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
OA12937A (en) * 2002-10-09 2006-10-13 Pfizer Prod Inc Thiazole compounds for the treatment of neurodegenerative disorders.
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
MXPA05012196A (es) * 2003-05-12 2006-02-08 Pfizer Prod Inc Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
JP2007501244A (ja) * 2003-08-06 2007-01-25 ファイザー・プロダクツ・インク 神経変性障害治療用オキサゾール化合物
CA2551142A1 (fr) * 2004-01-16 2005-08-11 Sanofi-Aventis Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
ATE517098T1 (de) 2004-01-16 2011-08-15 Sanofi Sa Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
ES2389062T3 (es) * 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
CN109071503A (zh) * 2016-03-31 2018-12-21 默克专利有限公司 用于抑制亲环素的化合物及其用途
ES2958118T3 (es) 2018-01-18 2024-02-01 Daiichi Sankyo Co Ltd Derivado de dihidroindolizinona
JP7553030B2 (ja) 2019-07-08 2024-09-18 国立大学法人東京工業大学 ジヒドロインドリジノン誘導体を用いたインスリン産生細胞の作製法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016751A1 (es) * 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
CA2272065A1 (en) 1996-11-22 1998-05-28 Thomas E. Mabry N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
AU749658C (en) * 1996-12-23 2004-04-29 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
HRP980093A2 (en) 1997-02-28 1998-12-31 Lilly Co Eli Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds
EP1131634A2 (de) * 1998-09-30 2001-09-12 Elan Pharmaceuticals, Inc. Bestimmung des mechanismus der beta-amyloid-peptid-erzeugung
WO2000024392A1 (en) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS

Also Published As

Publication number Publication date
US20040171643A1 (en) 2004-09-02
EP1417189B1 (de) 2005-12-14
TWI318974B (en) 2010-01-01
EP1417189A1 (de) 2004-05-12
US7288659B2 (en) 2007-10-30
WO2003014095A1 (fr) 2003-02-20
DE60208044T2 (de) 2006-08-17
AR039059A1 (es) 2005-02-09
JP2005500370A (ja) 2005-01-06
ATE312828T1 (de) 2005-12-15
DK1417189T3 (da) 2006-05-08
US20080058380A1 (en) 2008-03-06
ES2254773T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
DE60203917D1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate, deren herstellung und deren therapeutische verwendung
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE284886T1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
DE50209483D1 (de) Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE60336907D1 (de) Spirobifluorenderivate, deren herstellung und deren verwendung
DE60209779D1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE60323754D1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE231869T1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE60235547D1 (de) En daraus, deren herstellung und verwendung
DE60130834D1 (de) Zusammensetzungen gegen schlechte Gerüche, deren Herstellung und Verwendung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE60307632D1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE357448T1 (de) Benzoxazinonderivative, deren herstellung und verwendung
DE602004017463D1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
DE50002417D1 (de) 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung
ATE261959T1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
DE60103054D1 (de) Phenyloxazol-1,4-diazabicyclo[3.2.2]nonanderivate, ihre herstellung und ihre therapeutische verwendung
DE60005690D1 (de) Titanverbindungen, deren herstellung und verwendung
DE60321372D1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

R082 Change of representative

Ref document number: 1417189

Country of ref document: EP

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE